Unknown PHASE2 INTERVENTIONAL 1-arm NCT05024266

Tislelizumab Combined With Chemotherapy as Neoadjuvant Therapy for Stage IIIA-IIIB (N2) Lung Squamous Cell Carcinoma (TACT)

Tislelizumab Combined With Albumin Paclitaxel + Carboplatin as Neoadjuvant Therapy for Patients With Stage IIIA-IIIB (N2) Lung Squamous Cell Carcinoma: A Single-arm, Single-center, Exploratory Phase II Clinical Study

Sponsor: First Affiliated Hospital of Zhejiang University

Conditions Immunotherapy Lung Squamous Cell Carcinoma Neoadjuvant Therapy

Interventions Tislelizumab

Updated 4 times since 2021 Last updated: Aug 22, 2021 Started: Aug 1, 2021 Primary completion: Aug 31, 2022 Completion: Aug 31, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Immunotherapy and Lung Squamous Cell Carcinoma, this trial is ongoing. The trial is conducted by First Affiliated Hospital of Zhejiang University and has accumulated 4 data snapshots since 2021. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Oct 2023 — Jul 2024 [monthly]

Unknown Status PHASE2

Status: Recruiting → Unknown Status
Sep 2021 — Oct 2023 [monthly]

Recruiting PHASE2

First recorded

Aug 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

First Affiliated Hospital of Zhejiang University

Data source: First Affiliated Hospital of Zhejiang University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hangzhou, China